Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines
Respiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/12/10/1259 |
| _version_ | 1797572631675797504 |
|---|---|
| author | Xanthippi Topalidou Alexis M. Kalergis Georgios Papazisis |
| author_facet | Xanthippi Topalidou Alexis M. Kalergis Georgios Papazisis |
| author_sort | Xanthippi Topalidou |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic and pathophysiological evidence of the virus, including various vaccine technologies. The pipeline of RSV vaccine development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, and recombinant vector-based vaccine candidates targeting different virus proteins. The availability of vaccine candidates of various technologies enables adjustment to the individualized needs of each vulnerable age group. Arexvy<sup>®</sup> (GSK), followed by Abrysvo<sup>®</sup> (Pfizer), is the first vaccine available for market use as an immunizing agent to prevent lower respiratory tract disease in older adults. Abrysvo is additionally indicated for the passive immunization of infants by maternal administration during pregnancy. This review presents the RSV vaccine pipeline, analyzing the results of clinical trials. The key features of each vaccine technology are also mentioned. Currently, 24 vaccines are in the clinical stage of development, including the 2 licensed vaccines. Research in the field of RSV vaccination, including the pharmacovigilance methods of already approved vaccines, promotes the achievement of successful prevention. |
| first_indexed | 2024-03-10T20:58:44Z |
| format | Article |
| id | doaj.art-6f65856c319441e1b7384f037215c8b3 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T20:58:44Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-6f65856c319441e1b7384f037215c8b32023-11-19T17:40:47ZengMDPI AGPathogens2076-08172023-10-011210125910.3390/pathogens12101259Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved VaccinesXanthippi Topalidou0Alexis M. Kalergis1Georgios Papazisis2Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceMillennium Institute of Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8320000, ChileDepartment of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceRespiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic and pathophysiological evidence of the virus, including various vaccine technologies. The pipeline of RSV vaccine development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, and recombinant vector-based vaccine candidates targeting different virus proteins. The availability of vaccine candidates of various technologies enables adjustment to the individualized needs of each vulnerable age group. Arexvy<sup>®</sup> (GSK), followed by Abrysvo<sup>®</sup> (Pfizer), is the first vaccine available for market use as an immunizing agent to prevent lower respiratory tract disease in older adults. Abrysvo is additionally indicated for the passive immunization of infants by maternal administration during pregnancy. This review presents the RSV vaccine pipeline, analyzing the results of clinical trials. The key features of each vaccine technology are also mentioned. Currently, 24 vaccines are in the clinical stage of development, including the 2 licensed vaccines. Research in the field of RSV vaccination, including the pharmacovigilance methods of already approved vaccines, promotes the achievement of successful prevention.https://www.mdpi.com/2076-0817/12/10/1259respiratory syncytial virus (RSV)vaccine developmentpreventionlower respiratory tract infection (LRTI)vaccine candidatessubunit vaccine |
| spellingShingle | Xanthippi Topalidou Alexis M. Kalergis Georgios Papazisis Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines Pathogens respiratory syncytial virus (RSV) vaccine development prevention lower respiratory tract infection (LRTI) vaccine candidates subunit vaccine |
| title | Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines |
| title_full | Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines |
| title_fullStr | Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines |
| title_full_unstemmed | Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines |
| title_short | Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines |
| title_sort | respiratory syncytial virus vaccines a review of the candidates and the approved vaccines |
| topic | respiratory syncytial virus (RSV) vaccine development prevention lower respiratory tract infection (LRTI) vaccine candidates subunit vaccine |
| url | https://www.mdpi.com/2076-0817/12/10/1259 |
| work_keys_str_mv | AT xanthippitopalidou respiratorysyncytialvirusvaccinesareviewofthecandidatesandtheapprovedvaccines AT alexismkalergis respiratorysyncytialvirusvaccinesareviewofthecandidatesandtheapprovedvaccines AT georgiospapazisis respiratorysyncytialvirusvaccinesareviewofthecandidatesandtheapprovedvaccines |